Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Alprazolam + sulpiride** is a combination of two pharmaceutical agents: alprazolam, a benzodiazepine anxiolytic, and sulpiride, a substituted benzamide antipsychotic. Alprazolam acts as a central nervous system depressant by enhancing the inhibitory activity of the GABA(A) receptor, resulting in anxiolytic, sedative, and muscle relaxant effects. Sulpiride acts primarily as a selective antagonist of the dopamine D2 (and to a lesser extent, D3) receptors, exerting antipsychotic action, particularly in schizophrenia and other psychotic disorders. The combination is used off-label in some psychiatric settings to manage symptoms involving severe anxiety with psychosis or depression, but there is no evidence of a fixed-dose combination product being widely approved for this indication. Caution is warranted when using these drugs together due to an increased risk of central nervous system depression, requiring close monitoring and dose adjustment by a healthcare provider[1][2][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on alprazolam + sulpiride.